Edition:
United States

Nymox Pharmaceutical Corp (NYMX.OQ)

NYMX.OQ on NASDAQ Stock Exchange Capital Market

3.22USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$3.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
153,755
52-wk High
$5.77
52-wk Low
$1.62

NYMX.OQ

Chart for NYMX.OQ

About

Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging... (more)
No analyst recommendations are available for NYMX.OQ.

Overall

Beta: 0.74
Market Cap(Mil.): $147.46
Shares Outstanding(Mil.): 47.88
Dividend: --
Yield (%): --

Financials

  NYMX.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.34 -- --
ROI: -- -1.09 14.95
ROE: -- -2.39 16.29

BRIEF-Nymox reports additional positive data from fexapotide BPH phase 3 trial

* Nymox reports additional positive results from completed fexapotide BPH phase 3 studies showing significant early response and first-line efficacy

Nov 29 2016

BRIEF-Nymox reports successful new phase 3 long-term Fexapotide repeat injection BPH trial results

* Nymox reports successful new phase 3 long-term fexapotide repeat injection bph trial results: lasting symptomatic improvement up to 6 years after single repeated treatment

Oct 11 2016

BRIEF-Nymox Pharmaceutical announces new long-term fexapotide placebo crossover study results

* Nymox reports successful new long-term fexapotide placebo crossover study results: major reduction in incidence of surgery

Aug 24 2016

BRIEF-Nymox Pharmaceutical announces prostate drug progress

* Says fexapotide has completed 2 long-term large phase 3 BPH studies in U.S.

Aug 11 2016

BRIEF-Nymox Pharmaceutical reports results of prostate cancer study

* Nymox reports long-term prostate cancer results in 7 year prospective study of 995 u.s. Middle-Aged and elderly men without cancer

Jun 22 2016

Competitors

  Price Chg
Siemens AG (SIEGn.DE) €108.30 -0.70
Johnson & Johnson (JNJ.N) $111.94 -0.02
Pfizer Inc. (PFE.N) $31.59 -0.04
Novartis AG (NOVN.S) CHF69.30 -0.20
Merck & Co., Inc. (MRK.N) $60.25 -0.88
Roche Holding Ltd. (ROG.S) CHF223.30 +1.20
Roche Holding Ltd. (RO.S) CHF226.20 +0.20
Abbott Laboratories (ABT.N) $38.43 +0.53
AstraZeneca plc (AZN.L) 4,007.50p -26.00
Eli Lilly and Co (LLY.N) $67.26 -0.45

Earnings vs. Estimates